Efficacy and safety of crisaborole ointment, a novel, nonsteroidal phosphodiesterase 4 (PDE4) inhibitor for the topical treatment of atopic dermatitis (AD) in children and adults.

Autor: Paller AS; Northwestern University, Feinberg School of Medicine, Chicago, Illinois. Electronic address: APaller@nm.org., Tom WL; Rady Children's Hospital-San Diego, San Diego, California; University of California, San Diego, La Jolla, California., Lebwohl MG; Icahn School of Medicine at Mount Sinai, New York, New York., Blumenthal RL; Anacor Pharmaceuticals, Inc, Palo Alto, California., Boguniewicz M; National Jewish Health, Denver, Colorado; University of Colorado School of Medicine, Denver, Colorado., Call RS; Clinical Research Partners, Richmond, Virginia., Eichenfield LF; Rady Children's Hospital-San Diego, San Diego, California; University of California, San Diego, La Jolla, California., Forsha DW; Jordan Valley Dermatology and Research Center, West Jordan, Utah., Rees WC; Pi-Coor Clinical Research, Burke, Virginia., Simpson EL; Oregon Health and Science University, Portland, Oregon., Spellman MC; Anacor Pharmaceuticals, Inc, Palo Alto, California., Stein Gold LF; Henry Ford Health System, Detroit, Michigan., Zaenglein AL; Pennsylvania State University, Hershey, Pennsylvania., Hughes MH; Anacor Pharmaceuticals, Inc, Palo Alto, California., Zane LT; Anacor Pharmaceuticals, Inc, Palo Alto, California., Hebert AA; University of Texas Health Science Center Houston, Houston, Texas.

Publikováno v: Journal of the American Academy of Dermatology [J Am Acad Dermatol] 2016 Sep; Vol. 75 (3), pp. 494-503.e6. Date of Electronic Publication: 2016 Jul 11.